CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation

Summary

The primary objective of the trial is to evaluate efficacy and safety of delayed introduction (up to 30 days post-transplantation in patients without signs of acute rejection that had received an aIL-2 induction and MMF) of either cyclosporine or everolimus versus a 5-day delay of cyclosporine in combination with MMF.

Timeline

Start

2011-06

Primary completion

2014-07

Completion

2014-12

Drugs

Indications